Skip to main content
SpringerLink
Log in

Screening Strategies for Detecting Immunotherapeutic Agents

  • Chapter
The Pharmacology of Lymphocytes

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 85))

  • 122 Accesses

Abstract

Immunotherapeutics are empirically defined as natural or synthetic pharmacologic agents which mediate therapeutic benefit through their ability to modulate some aspect of immune function. Recently, interest in immunotherapeutic agents has increased, primarily owing to a rapidly expanding knowledge of the immune system and to an awareness that many important human diseases are associated with abnormal immune function of pathologic significance (Aiuti et al. 1986). This has led to the emergence of immunopharmacology as a recognized scientific discipline. This field encompasses the pharmacologic regulation of immune responses, the development of immunologically based assays and their research and development applications, the preparation and utilization of monoclonal antibodies and cytokines as pharmacologic tools and therapeutic agents, and the discovery and development of immunotherapeutic agents. The immunopharmacologist must conjoin fundamental pharmacology with modern immunology in an attempt to determine the biologic and biochemical effects of synthetic and natural products on immune responsiveness, elucidate the mechanism (or mechanisms) through which such effects are mediated, and evaluate the clinical potential of such agents (Chirigos and Talmadge 1985).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adams DO, Hamilton TA (1984) The cell biology macrophage activation. Ann Rev Immunol 2: 283–318

    Article  CAS  Google Scholar 

  • Aiuti F, Rosen F, Cooper MD (1986) Recent advances in primary and acquired immunodeficiencies. Serono Symp Ser 28: 1–434

    Google Scholar 

  • Amery WK (1981) Cancer immunotherapy: some critical comments regarding immunological monitoring. Int J Immunopharmacol 3: 339–348

    Article  PubMed  CAS  Google Scholar 

  • Auron PE, Webb A, Rosenwasser LJ, Mucci SF, Rich A, Wolff S, Dinarello CA (1984) Nucleotide sequence of human monocyte interleukin 1 precursor DNA. Proc Natl Acad Sci USA 81: 7907–7911

    Article  PubMed  CAS  Google Scholar 

  • Bach JF, Chatenoud L (1982) The significance of T cell subsets defined by monoclonal antibodies in human diseases. Ann Immunol 133: 131–136

    Google Scholar 

  • Bakke A, Kinkland PA, Kitridou RC, Quismorio FP, Rea T, Ehresmann GR, Horowitz DA (1983) T-lymphocyte subsets in systemic lupus erythematosus. Arthritis Rheum 26: 745–750

    Article  PubMed  CAS  Google Scholar 

  • Chang J, Gilman SC, Lewis AJ (1986) Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL 1 action. J Immunol 136: 1283–1287

    PubMed  CAS  Google Scholar 

  • Chirigos MA, Talmadge JE (1985) Immunotherapeutic agents: their role in cellular immu-nity and their therapeutic potential. Springer Semin Immunopathol 8: 327–346

    Article  PubMed  CAS  Google Scholar 

  • Cunningham AJ, Szenberg A (1968) Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology 14: 599–600

    PubMed  CAS  Google Scholar 

  • Dillman RO, Koziol JA (1983) Statistical approach to immunosuppression classification using lymphocyte surface markers and functional assays. Cancer Res 43: 417–421

    PubMed  CAS  Google Scholar 

  • Dinarello CA (1984) Interleukin 1. Rev Infect Dis 6: 51–95

    Article  CAS  Google Scholar 

  • Dorf ME, Benacerraf B (1984) Suppressor cells and immunoregulation. Ann Rev Immunol 2: 127–158

    Article  CAS  Google Scholar 

  • Duke O, Panayi GS, Janossy G, Poulter LW, Tidman N (1983) Analysis of T-cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis 42: 357–361

    Article  PubMed  CAS  Google Scholar 

  • Eilber FR, Nizze JA, Morton DL (1975) Sequential evaluation of general immune competence in cancer patients: correlation with clinical course. Cancer 55: 660–665

    Article  Google Scholar 

  • Farrar JJ, Benjamin WR, Cheng L, Pawson BA (1984) Interleukin 2. Ann Rep Med Chem 19: 191–200

    CAS  Google Scholar 

  • Farrar WL, Taguchi M (1985) Interleukin 2 stimulation of protein kinase C membrane as- sociation: evidence for IL-2 receptor phosphorylation. Lymphokine Res 4: 87–93

    PubMed  CAS  Google Scholar 

  • Fathman CG (1982) Regulation of the immune response. In: Luderer AA, Weetal HH (eds) Clinical cellular immunology — molecular and therapeutic reviews. Humana, New Jersey, pp 31–66

    Chapter  Google Scholar 

  • Gearing AJH, Johnstone AP, Thorpe R (1985) Production and assay of the interleukins. J Immunol Methods 83: 1–27

    Article  PubMed  CAS  Google Scholar 

  • Gilman SC (1984) Lymphokines in immunological aging. Lymphokine Res 3:117–123 Gilman SC, Lewis AJ (1985) Immunomodulatory drugs in the treatment of rheumatoid arthritis. In: Rainsford KD (ed) Antiinflammatory and antirheumatic drugs, vol 3. CRC Press, Florida, pp 127–154

    Google Scholar 

  • Gilman SC, Lewis AJ (1986) Immunopharmacological approaches to drug development. In: Williams M, Malick JB (eds) Drug discovery and development. Humana, New Jersey, pp 227–256

    Google Scholar 

  • Goldstein AL, Low TLK, Thurman GB, Zatz M, Hall NR, McClure JE, Hu SK, Schulof RS (1982) Thymosins and other hormone-like factors of the thymus gland. In: Mihich E (ed) Immunological approaches to cancer therapeutics. Wiley, New York, pp 137–190

    Google Scholar 

  • Hansen JM, Rumjanek VM, Morley J (1982) Mediators of cellular immune reactions. Pharmacol Ther 17: 165–198

    Article  Google Scholar 

  • Herberman RB (1985) Design of clinical trials with biological response modifiers. Cancer Treat Rep 69: 1161–1164

    PubMed  CAS  Google Scholar 

  • Herberman RB, Holden HT (1978) Natural cell-mediated immunity. Adv Cancer Res 27: 305–377

    Article  PubMed  CAS  Google Scholar 

  • Hurst N, Nuki G (1981) The macrophage — origins, functions, and role in the rheumatoid diseases. In: Dick WC (ed) Immunological aspects of rheumatology. Elsevier/NorthHolland, New York, pp 183–207

    Chapter  Google Scholar 

  • Lewis AJ, Gilman SC (1987) Actions of novel immunoregulants useful in the treatment of rheumatoid arthritis as may be relevant to their toxicity. In: Rainsford KD, Velo GP (eds) Toxicity of antiinflammatory and antirheumatic drugs. Part II. Studies in major organ systems. MTP Press, Lancaster, VK, pp 253–269, CRC Press, Florida

    Google Scholar 

  • Lewis AJ, Parker H, Diluigi J, Datko L, Carlson RP (1981–82) Immunomodulation of delayed hypersensitivity to methylated bovine serum albumin in mice using subliminal and normal sensitization procedures. J Immunopharmacol 3:289–307

    Google Scholar 

  • Lewis AJ, Carlson RP, Chang J (1985) Experimental models of inflammation. In: Bonta IL, Bray MA, Parnham MJ (eds) The pharmacology of inflammation. Elsevier, New York, pp 371–397 (Handbook of inflammation, vol 5 )

    Google Scholar 

  • March CB, Mosley B, Larsen A, Cerretti P, Braedt V, Prive V, Gillis S, Henney CS, Kronheim SR, Grabstein K, Conlon PJ, Hopp TP, Cosman D (1985) Cloning, sequence, and expression of two distinct human interleukin 1 complementary DNAs. Nature 315: 641–647

    Article  PubMed  CAS  Google Scholar 

  • Merluzzi VJ, Last-Barney K (1985) Potential use of human interleukin 2 as an adjunct for the therapy of neoplasia, immunodeficiency and infections disease. J Biol Response Mod 7: 31–39

    CAS  Google Scholar 

  • Morimoto C, Schlossman SF, Reinherz EL (1983) Use of monoclonal antibodies in the study of autoimmunity and immunodeficiency. In: Haynes BF, Eisenbath GS (eds) Monoclonal antibodies. Academic, Florida, pp 1–21

    Google Scholar 

  • Olsson L (1983) Monoclonal antibodies in clinical immunobiology. Derivation, potential and limitations. Allergy 38: 145–154

    Article  PubMed  CAS  Google Scholar 

  • Parker CW (1973) The immunotherapy of cancer. Pharmacol Rev 25: 325–342

    PubMed  CAS  Google Scholar 

  • Pinskey CM (1985) Applicability of phase I trial results in the design of phase II and III biological response modifier trials. Cancer Treat Rep 69: 1171–1173

    Google Scholar 

  • Reinherz EL, Schlossman SF (1980) The differentiation and function of human T lymphocytes. Cell 19: 821–827

    Article  PubMed  CAS  Google Scholar 

  • Reisfeld RA, Sell S (1985) Monoclonal antibodies and cancer therapy. Liss, New York, pp 1–585

    Google Scholar 

  • Renoux G (1980) Trends in immunopotentiation. Int J Immunopharmacol 2: 1–6

    Article  Google Scholar 

  • Renoux G (1986) Characterization of immunotherapeutic agents: the example of imuthiol. Methods Find Exp Clin Pharmacol 8: 45–50

    PubMed  CAS  Google Scholar 

  • Robb RJ (1984) Interleukin 2• the molecule and its function. Immunol Today 5: 203–209

    Article  CAS  Google Scholar 

  • Rocklin RE, Hemady Z, Matloff S, Kiselis I, Lima M (1984) Correction of an in vitro immunoregulatory defect in atopic subjects by the immunostimulatory drug fanetizole mesylate (CP-48,410). Int J Immunopharmacol 6: 1–8

    Article  PubMed  CAS  Google Scholar 

  • Rogers CM, Rogers TJ, Gilman SC (1985) Effects of Wy-18,251 (3 p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid), levamisole and indomethacin on the generation of murine T suppressor cells in vitro. J Immunopharmacol 7: 479–488

    Article  PubMed  CAS  Google Scholar 

  • Roitt IM, Male D, Young A, Jones M, Nivehaus L, Corbett M, Hay FC (1982) Autoimmune phenomena in rheumatoid arthritis. Adv Inflammation Res 3: 49–58

    Google Scholar 

  • Rosenberg SA, Lotze MT, Murl LM, Leitman S, Chang AE, Ettinghauser SE, Matory YL, Skibbe JM, Shiloni E, Vetto JT (1985) Observations on the administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

    Article  PubMed  CAS  Google Scholar 

  • Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA, Old LJ (1985) High affinity binding of ‘I-labeled human tumor necrosis factor ( LuKII) to specific cell surface receptors. J Exp Med 162: 1099–1104

    Google Scholar 

  • Scheinberg MA, Santos L, Mendes N, Musatti C (1978) Decreased lymphocyte response to PHA, Con-A, and calcium ionophore (A23187) in patients with RA and SLE, and reversal with levamisole in rheumatoid arthritis. Arthritis Rheum 21: 326–329

    Article  PubMed  CAS  Google Scholar 

  • Sigel MM, Ghaffer A, Paul R, Licher W, Wellham L, McCumber LJ, Huggins EM Jr (1982) Immunosuppressive agents — their action on inductive and regulatory pathways. The differential effects of agents used clinically and experimentally in the treatment of cancer. In: Luderer AA, Weetal HH (eds) Clinical cellular immunology — molecular and therapeutic reviews. Humana, New Jersey, pp 145–211

    Chapter  Google Scholar 

  • Siskind GW, Christian CL, Litwin SD (1975) Immune depression and cancer. Grune and Stratton, New York, pp 1–209

    Google Scholar 

  • Sorkin E, Del Ray A, Besedovsky HO (1981) Neuroendocrine control of the immune response. In: Steinberg CM, Lefkovits I (eds) The immune system, vol 1. Karger, Basel, pp 340–357

    Google Scholar 

  • Steinberg AD (1973) Efficacy of immunosuppressive drugs in rheumatic diseases. Arthritis Rheum 16: 92–96

    Article  PubMed  CAS  Google Scholar 

  • Strander H, Einhorn S (1982) Interferon and cancer: faith, hope and reality. Am J Clin On-col 5: 297–301

    CAS  Google Scholar 

  • Talmadge JE, Herberman (1986) The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70: 171–182

    PubMed  CAS  Google Scholar 

  • Talmadge JE, Benedict KL, Uithoven KA, Lenz BF (1984 a) The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five). Immunopharmacology 7:17–26

    Article  CAS  Google Scholar 

  • Talmadge JE, Oldham RK, Fidler IJ (1984 b) Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers. J Biol Response Mod 3:88–102

    CAS  Google Scholar 

  • Urbaniak SJ, White AG, Barclay GR, Wood SM, Kay AB (1979) Tests of immune function. In: Weir DM (ed) Application of immunological methods. Blackwell, Oxford, pp 47.1–47.3 (Handbook of experimental immunology, vol 3 )

    Google Scholar 

  • Veys E, Hermanns P, Goldstein G, Kung PC, Schindler J, Symoens J, Van Wauve J (1982) T-cell subpopulations determined by monoclonal antibodies in RA. Influence of immunomodulating agents. Adv Inflammation Res 3: 155–164

    Google Scholar 

  • Wofsy D (1985) Strategies for treating autoimmune disease with monoclonal antibodies. West J Med 143: 804–809

    PubMed  CAS  Google Scholar 

  • Zalcberg JR (1985) Monoclonal antibodies to drugs: novel diagnostic and therapeutic reagents. Pharmacol Ther 28: 273–285

    Article  PubMed  CAS  Google Scholar 

  • Zvaifler NJ (1973) The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 16: 265–301

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. C. Gilman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. T. Maguire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. J. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Research Department, CIBA-GEIGY AG, CH-4002, Basel, Switzerland

    Michael A. Bray Ph. D.

  2. Pharmaceutical Division, Preclinical Research, SANDOZ Ltd., CH-4002, Basel, Switzerland

    John Morley Ph. D., FRC Path.

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gilman, S.C., Maguire, R.T., Lewis, A.J. (1988). Screening Strategies for Detecting Immunotherapeutic Agents. In: Bray, M.A., Morley, J. (eds) The Pharmacology of Lymphocytes. Handbook of Experimental Pharmacology, vol 85. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73217-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73217-1_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73219-5

  • Online ISBN: 978-3-642-73217-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation